You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.
Julia Karow tracks trends in next-generation sequencing for research and clinical applications for GenomeWeb. Follow her on Twitter at @Julia_Karow.
The startup wants to serve the 50 percent or so of genetic disease patients who haven't obtained a molecular diagnosis despite extensive testing.
A number of diagnostic labs have considered saliva-based SARS-CoV-2 testing but decided against it, while other groups continue to pursue it.
The firm saw revenues grow 10 percent in Q2, in part driven by PCR-based COVID-19 testing, as it increased production capacity to 10 million tests per week.
The new pore, a complex between E. coli CsgG and part of CsgF, called certain homopolymers more accurately than an engineered version of CsgG.
The North Carolina State University team is working on scaling the technology further and may form a company to develop it commercially.
Several groups are developing diagnostic viral genome sequencing assays and panels, which promise high sensitivity and additional information on viral origin and spread.
The first version of the platform, which the company submitted for Emergency Use Authorization to the US FDA last week, analyzes RNA extracted from a swab.
Assays like SwabSeq, Dx-Seq, and LAMP-Seq promise to analyze tens to hundreds of thousands of samples in parallel but might be constrained by sample availability.
Replacing nasopharyngeal swabs with saliva samples or nasal swabs could increase throughput and convenience, as well as relieve reagent and equipment shortages.
The firm is looking into options for partnerships to bring a COVID-19 serology test to market, which could leverage its large installed base of instruments.
Howard Hughes Medical Institute will be requiring its researchers to publish their work so it is immediately accessible to the public, ScienceInsider writes.
The Huffington Post reports that Francis Collins, the director of the US National Institutes of Health, has urged Americans to recommit to reason.
About 150 million rapid coronavirus tests purchased by the US federal government are to be distributed to nursing homes, colleges, and the states, according to the New York Times.
In Nature this week: multi-omic analysis of Alzheimer's disease brain samples, de novo assembly of a diploid potato, and more.